Fibronostics

Fibronostics, established in 2015 and headquartered in Orlando, Florida, is a healthcare technology company that specializes in the development of non-invasive, AI-based diagnostic solutions. The company's primary focus is on liver disease detection and monitoring, offering the LiverFASt suite of solutions. These solutions use serum biomarker concentrations, adjusted for age, gender, and BMI, to provide insights into a patient's liver health, fibrotic activity, inflammation, and steatosis levels. Additionally, Fibronostics develops predictive technologies to track cardio-metabolic diseases, idiopathic pulmonary fibrosis, and chronic renal diseases, enabling early detection and efficient monitoring.